Evaluation of gut microbiota in Parkinson’s disease using gas chromatography with mass spectrometric detection

Cover Page

Cite item

Full Text


The paper presents preliminary results of a comparative study assessing the gut microbiota in patients with Parkinson's disease and the control group using the gas chromatography with mass spectrometric detection. Sixteen patients with stage 3 Parkinson's disease and 94 age-matched persons without Parkinson's disease were examined. It was revealed that the total number of microbial markers in parietal intestinal microbiota in patients with Parkinson's disease was increased by 43% compared with the control group. This increase is due to a 2-fold increase in the number of conditional-pathogenic flora, and at the same time there was a 2-fold decrease in the number of microbial markers of useful microflora. The obtained results may be regarded as preliminary and need to be assessed in a large cohort of patients with Parkinson’s disease. It is also necessary to assess the relationship between immune status and changes in microbiota, and to develop methods of correction of the revealed changes. Analysis of the efficiency of restoration of qualitative and quantitative composition of microbiota should be carried out using methods for the assessment of bioequivalence levodopa dose.

About the authors

Igor V. Krasakov

The Nikiforov All-Russian Centre of Emergency and Radiation Medicine; S.M. Kirov Military Medical Academy

Author for correspondence.
Email: ikrasakov@gmail.com
Russian Federation, St. Petersburg

Igor V. Litvinenko

S.M. Kirov Military Medical Academy

Email: ikrasakov@gmail.com
ORCID iD: 0000-0001-8988-3011

D. Sci. (Med.), Professor, Head, Department of nervous diseases, Chief neurologist of the Russian Ministry of Defense

Russian Federation, St. Petersburg

Gennadiy G. Rodionov

Nikiforov Russian Center of Emergency and Radiation Medicine

Email: ikrasakov@gmail.com
Russian Federation, St. Petersburg

Igor I. Shantyr

Nikiforov Russian Center of Emergency and Radiation Medicine

Email: ikrasakov@gmail.com
Russian Federation, St. Petersburg

Ekaterina V. Svetkina

Nikiforov Russian Center of Emergency and Radiation Medicine

Email: ikrasakov@gmail.com
Russian Federation, St. Petersburg


  1. Illarioshkin S.N., Levin O.S. (eds.) Rukovodstvo po diagnostike i lecheniyu bolezni Parkinsona [A Guide to the Diagnosis and Treatment of Parkinson's Disease]. Moscow, 2017. 336 p. (In Russ.)
  2. Levin O.S., Fedorova N.V. Bolezn' Parkinsona [Parkinson's Disease]. Moscow, 2016. 384 p. (In Russ.)
  3. Litvinenko I.V. Bolezn' Parkinsona [Parkinson's Disease]. Moscow, 2006. 216 p. (In Russ.)
  4. Ueki A., Otsuka M. Life style risks of Parkinson's disease: association between decreased water intake and constipation. J Neurol 2004; 251(suppl 7): vII8–23. doi: 10.1007/s00415-004-1706-3. PMID: 15505750.
  5. Cersosimo M.G., Benarroch E.E. Pathological correlates of gastrointestinal dysfunction in Parkinson's disease. Neurobiol Dis 2012; 46: 559–564. doi: 10.1016/j.nbd.2011.10.014. PMID: 22048068.
  6. Braak H., de Vos R.A., Bohl J., Del Tredici K. Gastric alpha-synuclein immunoreactive inclusions in Meissner's and Auerbach's plexuses in cases staged for Parkinson's disease-related brain pathology. Neurosci Lett 2006; 396: 67–72. doi: 10.1016/j.neulet.2005.11.012. PMID: 16330147.
  7. Franzosa E.A., Huang K., Meadow J.F. et al. Identifying personal microbiomes using metagenomic codes. Proc Natl Acad Sci USA 2015; 112: E2930–E2938. doi: 10.1073/pnas.1423854112. PMID: 25964341.
  8. Browne H.P., Forster S.C., Anonye B.O. et al. Culturing of ‘unculturable’ human microbiota reveals novel taxa and extensive sporulation. Nature 2016; 533: 543–546. doi: 10.1038/nature17645. PMID: 27144353.
  9. Cryan J.F., Dinan T.G. Mind-altering microorganisms: the impact of the gut microbiota on brain and behaviour. Nat Rev Neurosci 2012; 13: 701–712. doi: 10.1038/nrn3346. PMID: 22968153.
  10. Forsyth C.B., Shannon K.M., Kordower J.H. et al. Increased intestinal permeability correlates with sigmoid mucosa alpha-synuclein staining and endotoxin exposure markers in early Parkinson's disease. PLoS One 2011; 6: e28032. doi: 10.1371/journal.pone.0028032. PMID: 22145021.
  11. Keshavarzian A., Green S.J., Engen P.A. et al. Colonic bacterial composition in Parkinson's disease. Mov Disord 2015; 30: 1351–1360. doi: 10.1002/mds.26307. PMID: 26179554.
  12. Tan A.H., Mahadeva S., Thalha A.M. et al. Small intestinal bacterial overgrowth in Parkinson's disease. Parkinsonism Relat Disord 2014; 20: 535–540. doi: 10.1016/j.parkreldis.2014.02.019. PMID: 24637123.
  13. Scheperjans F., Aho V., Pereira P.A. et al. Gut microbiota are related to Parkinson's disease and clinical phenotype. Mov Disord 2015; 30: 350–358. doi: 10.1002/mds.26069. PMID: 25476529.
  14. Thakur A.K., Shakya A., Husain G.M. et al. Gut-microbiota and mental health: current and future perspectives. J Pharmacol Clin Toxicol 2014; 2: 1016.
  15. Cryan J.F., Dinan T.G. Mind-altering microorganisms: the impact of the gut microbiota on brain and behaviour. Nat Rev Neurosci 2012; 13: 701–712. doi: 10.1038/nrn3346. PMID: 22968153.
  16. Wall R., Cryan J.F., Ross R.P. et al. Bacterial neuroactive compounds produced by psychobiotics. Adv Exp Med Biol 2014; 817: 221–239. doi: 10.1007/978-1-4939-0897-4_10. PMID: 24997036.
  17. Parashar A., Udayabanu M. Gut microbiota: Implications in Parkinson's disease. Parkinsonism Relat Disord. 2017; 38: 1–7. doi: 10.1016/j.parkreldis.2017.02.002. PMID: 28202372.
  18. Diaz Heijtz R., Wang S., Anuar F. et al. Normal gut microbiota modulates brain development and behavior. Proc Natl Acad Sci USA. 2011; 108: 3047–3052. doi: 10.1073/pnas.1010529108. PMID: 21282636.
  19. Matsumoto M., Kibe R., Ooga T. et al. Cerebral low-molecular metabolites influenced by intestinal microbiota: a pilot study. Front Syst Neurosci 2013; 7: 9. doi: 10.3389/fnsys.2013.00009. PMID: 23630473.
  20. Daubner S.C., Le T., Wang S. Tyrosine hydroxylase and regulation of dopamine synthesis. Arch Biochem Biophys 2011; 508: 1–12. doi: 10.1016/j.abb.2010.12.017. PMID: 21176768.
  21. Du Y., Ma Z., Lin S. et al. Minocycline prevents nigrostriatal dopaminergic neurodegeneration in the MPTP model of Parkinson's disease. Proc Natl Acad Sci USA. 2001; 98: 14 669–14 674. doi: 10.1073/pnas.251341998. PMID: 11724929.
  22. Radad K., Moldzio R., Rausch W.D. Minocycline protects dopaminergic neurons against long-term rotenone toxicity. Can J Neurol Sci 2010; 37: 81–85. doi: 10.1017/S0317167100009690. PMID: 20169778.
  23. Inamdar A.A., Chaudhuri A., O'Donnell J. The protective effect of minocycline in a paraquat-induced Parkinson's disease model in drosophila is modified in altered genetic backgrounds. Parkinsons Dis 2012; 2012: 938528. doi: 10.1155/2012/938528. PMID: 22900232.
  24. NINDS NET-PD Investigators. A randomized, double-blind, futility clinical trial of creatine and minocycline in early Parkinson disease. Neurology 2006; 66: 664–671. doi: 10.1212/01.wnl.0000201252.57661.e1. PMID: 16481597.
  25. Yang T., Santisteban M.M., Rodriguez V. et al. Gut dysbiosis is linked to hypertension. Hypertension 2015; 65: 1331–1340. doi: 10.1161/HYPERTENSIONAHA.115.05315. PMID: 25870193.
  26. Lotan D., Cunningham M., Joel D. Antibiotic treatment attenuates behavioral and neurochemical changes induced by exposure of rats to group a streptococcal antigen. PLoS One 2014; 9: e101257. doi: 10.1371/journal.pone.0101257. PMID: 24979049.
  27. Surwase S.N., Jadhav J.P. Bioconversion of L-tyrosine to L-DOPA by a novel bacterium Bacillus sp. JPJ. Amino Acids 2011; 41: 495–506. doi: 10.1007/s00726-010-0768-z. PMID: 20963458.
  28. LeBlanc J.G., Milani C., de Giori G.S. et al. Bacteria as vitamin suppliers to their host: a gut microbiota perspective. Curr Opin Biotechnol 2013; 24: 160–168. doi: 10.1016/j.copbio.2012.08.005. PMID: 22940212.
  29. Cassani E., Privitera G., Pezzoli G. et al. Use of probiotics for the treatment of constipation in Parkinson's disease patients. Minerva Gastroenterol Dietol 2011; 57: 117–121. doi: 10.1038/s41531-018-0042-8. PMID: 21587143.
  30. Mridula K.R., Borgohain R., Chandrasekhar Reddy V. et al. Association of Helicobacter pylori with Parkinson's Disease. J Clin Neurol 2017; 13: 181–186. doi: 10.3988/jcn.2017.13.2.181. PMID: 28406585.
  31. Senkovich O.A., Yin J., Ekshyyan V. et al. Helicobacter pylori AlpA and AlpB bind host laminin and influence gastric inflammation in gerbils. Infect Immun 2011; 79: 3106–3116. doi: 10.1128/IAI.01275-10. PMID: 21576328.
  32. Arai H., Furuya T., Mizuno Y., Mochizuki H. Inflammation and infection in Parkinson's disease. Histol Histopathol 2006; 21: 673–678. doi: 10.14670/HH-21.673. PMID: 16528677.
  33. Dobbs R.J., Dobbs S.M., Weller C. et al. Role of chronic infection and inflammation in the gastrointestinal tract in the etiology and pathogenesis of idiopathic parkinsonism. Part 1: eradication of Helicobacter in the cachexia of idiopathic parkinsonism. Helicobacter 2005; 10: 267–275. doi: 10.1111/j.1523-5378.2005.00331.x. PMID: 16104942.
  34. Fiddian-Green R.G. Helicobacter pylori eradication and L-dopa absorption in patients with PD and motor fluctuations. Neurology 2007; 68: 1085. doi: 10.1212/01.wnl.0000260440.07107.99. PMID: 17389325.
  35. Braniste V., Al-Asmakh M., Kowal C. et al. The gut microbiota influences blood-brain barrier permeability in mice. Sci Transl Med 2014; 6: 263ra158. doi: 10.1126/scitranslmed.3009759. PMID: 25411471.
  36. Anderson G., Seo M., Berk M. et al. Gut permeability and microbiota in Parkinson's disease: role of depression, tryptophan catabolites, oxidative and nitrosative stress and melatonergic pathways. Curr Pharm Des 2016; 22: 6142–6151. doi: 10.2174/1381612822666160906161513. PMID: 27604608.
  37. Litvinenko I.V., Krasakov I.V., Bisaga G.N. et al. [Modern conception of the pathogenesis of neurodegenerative diseases and therapeutic strategy]. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova 2017; (6) (suppl 2): 3–10. (In Russ.) doi: 10.17116/jnevro2017117623-10.
  38. Rodionov G.G., Shantyr I.I., Svetkina E.V. et al. [Evaluation of the wall intestinal microbiota of healthy people by gas chromatography – mass spectrometry method]. Translyatsionnaya meditsina 2017; 4(6): 34–42. (In Russ.) doi: 10.18705/2311-4495-2017-4-6-34-42.
  39. Budnikov G.K. (ed.) Problemy analiticheskoy khimii [Problems of Analytical Chemistry]. Moscow, 2010; 11: 293–368. (In Russ.)

Supplementary files

Supplementary Files

Copyright (c) 2018 Krasakov I.V., Litvinenko I.V., Rodionov G.G., Shantyr I.I., Svetkina E.V.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № ФС 77-83204 от 12.05.2022.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies